Clinical Trial

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Study acronym: ABLE-32
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Protocol Amendment History 5 changes
notable Trial sites expanded: 103 -> 106 locations 2026-08-07
notable Trial sites expanded: 98 -> 101 locations 2026-06-18
notable Trial sites expanded: 94 -> 97 locations 2026-05-13
notable Trial sites expanded: 82 -> 94 locations 2026-05-09
notable Trial sites expanded: 79 -> 82 locations 2026-05-01
Trial Details
NCT Number NCT06510374
Lead Sponsor Ferring Pharmaceuticals
Conditions Intermediate Risk Non-Muscle Invasive Bladder Cancer
Enrollment 454 participants
Start Date 2024-10-01
Primary Completion 2028-06-30 (estimated)
Study Completion 2031-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-06